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Recommendations for the Prevention and
Management of Chlamydia trachomatis  Infections,
1993
Summary
In 1985, CDC published Policy Guidelines for Prevention and Control of
Chlamydia trachomatis infections (1 ). Those guidelines highlighted the preva-
lence and morbidity of chlamydial infections and stressed the need to include
antibiotics effective against chlamydia when treating patients for urethritis, mu-
copurulent cervicitis, and pelvic inflammatory disease. The recommendations
presented in this report update the 1985 guidelines. In addition, these recom-
mendations propose a national strategy for reducing the morbidity of
chlamydial infections by detection and treatment and through the prevention of
transmission to uninfected persons. Such an effort is now possible because of
a) expanding educational efforts stimulated by the epidemic of acquired immu-
nodeficiency syndrome and other sexually transmitted diseases, and b) the
availability of chlamydia tests that are easy to use, economical, and accurate,
thereby allowing health-care providers to diagnose and treat infected persons
and their sex partners.
Education, screening, and sex partner referral require coordination of the
activities of several professionals, including educators, clinicians, microbiolo-
gists, outreach workers, and program managers. Because chlamydial infections
are common among adolescents and young adults throughout the United
States, health-care providers and other agencies serving these groups should
become more involved if a sufficiently large proportion of the chlamydia-in-
fected population is to be reached. Health departments should establish
consortia of these organizations to pool resources and to coordinate activities.
To facilitate such collaborations, this document outlines the elements of a
chlamydia prevention program. 
These recommendations were developed by CDC after consultation with ex-
perts attending a chlamydia prevention workshop held in Atlanta, Georgia,
March 26–28, 1991. Commentary from additional public health, medical, and
laboratory practitioners also was considered in developing these recommenda-
tions. 
INTRODUCTION
Chlamydia trachomatis  infections are common in sexually active adolescents and
young adults in the United States (CDC, unpublished review ). More than 4 million
chlamydial infections occur annually (2,3 ). Infection by this organism is insidious—
symptoms are absent or minor among most infected women and many men. This
large group of asymptomatic and infectious persons sustains transmission within a
community. In addition, these persons are at risk for acute illness and serious long-
term sequelae. The direct and indirect costs of chlamydial illness exceed $2.4 billion
annually (2–4 )*. 
*NOTE: Direct and indirect costs were calculated from figures previously published.
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Until recently, chlamydia prevention and patient care were impeded by the lack of
suitable laboratory tests for screening and diagnosis. Such tests are now available.
Through education, screening, partner referral, and proper patient care, public health
workers and health-care practitioners can combine efforts to decrease the morbidity
and costs resulting from this infection.
Prevalence of Chlamydial Infection
Adolescents and young adults are at substantial risk of becoming infected with
chlamydia. Unrecognized infection is highly prevalent in this group (CDC, unpublished
review ).
In the United States, published studies of sexually active females screened during
visits to health-care providers indicate that age is the sociodemographic factor most
strongly associated with chlamydial infection. Prevalence has been highest (>10%)
among sexually active, adolescent females (CDC, unpublished review ). The preva-
lence of chlamydial infection also has been higher among those patients who live in
inner cities, have a lower socioeconomic status, or are black (5–11 ). Although preva-
lences have been higher in these subgroups, with few exceptions prevalences are ≥5%
regardless of region of the country, urban/rural location of provider, or race/ethnicity
(CDC, unpublished review ). 
Fewer screening studies have been reported for men, but prevalences have been
>5% among young men seeking health care for reasons other than genitourinary tract
problems. Published reports of these studies from North America and Europe have
included male high school students (12 ), military personnel (13,14 ), semen donors
(15,16 ), adolescents in detention centers (17–20 ), and teens attending adolescent
clinics (17,20 ), adolescents attending university health centers (20,21 ), and chemical
dependency units (22 ). 
Clinical Spectrum of Chlamydial Infection Among Nonpregnant Women
Pelvic inflammatory disease (PID) accounts for most of the serious acute illness,
morbidity, and economic cost resulting from chlamydial infection. Treating women
with acute, symptomatic PID is not a sufficient prevention strategy because treatment
does not always prevent sequelae and because many women with tubal infection
have symptoms too mild or too nonspecific for them to seek treatment.
A woman’s exposure to chlamydia is usually a result of sexual intercourse. The site
of initial infection is most often the cervix; the urethra and the rectum may also be
infected (23–28 ). Chlamydia causes symptoms in a minority of infected women (9,
29-38 ). When symptoms occur, they include vaginal discharge and dysuria (9,23,25–
27,29–33,35–38 ). The ascension of lower, genitourinary tract infection to the
endometrium and fallopian tubes may cause lower abdominal pain and menstrual
abnormalities. Untreated infections among women often persist for months (7,34,
39–41 ). During this period, complications may develop, and many of these women
transmit their infection to others.
The proportion of women with chlamydial infection who develop infection of the
upper reproductive tract (endometritis, salpingitis, and pelvic peritonitis) is uncertain;
however, an estimated 8% of women with chlamydia also had overt salpingitis (42). A
second study of women with dual gonococcal and chlamydial infections, but who
were treated only for gonorrhea, revealed that 30% developed salpingitis during
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follow-up (43 ). Chlamydia, alone or with other microorganisms, has been isolated
from 5% to 50% of women seeking care for symptoms of PID (CDC, unpublished re-
view). Symptomatic PID prompts 2.5 million outpatient visits to physicians annually
(44,45 ). More than 275,000 women are hospitalized and more than 100,000 surgical
procedures are performed yearly because of PID (45 ). Both the diagnosis and the
treatment of PID are unsatisfactory: approximately 17% of women treated for PID will
be infertile; an equal proportion will experience chronic pelvic pain as a result of infec-
tion (46,47 ); and 10% who do conceive will have an ectopic pregnancy (48 ).
The importance of undetected, untreated fallopian tube infections as a cause of
infertility and ectopic pregnancy is clear. In two studies of chlamydia and PID in infer-
tile women, PID was the cause of the infertility in half of the women, and
anti-chlamydial antibody was strongly associated with a tubal etiology for infertility
(49,50 ). Of concern in these studies was the small proportion of women with tubal-
factor infertility who reported a past history of salpingitis. Other studies indicate that
many of these women may have had salpingitis, but were not treated because symp-
toms were absent or nonspecific (49,51–60 ). Unrecognized PID also may be a
contributor to the occurrence of ectopic pregnancies (60,61 ). Because chlamydial in-
fections are not usually associated with overt symptoms, prevention of infection is the
most effective means of preventing sequelae.
Pregnant women with chlamydial infection are at risk for postpartum PID. Postpar-
tum and perinatal disease are preventable by treating infected pregnant women and
their sex partners. Endometritis, and possibly salpingitis, developed among 10%–28%
of pregnant women with untreated chlamydial infection who underwent induced
abortions (27,62–64 ). Similarly, endometritis may develop during the late postpartum
period among 19%–34% of infected pregnant women who deliver vaginally and at-
term (65,66 ).
Clinical Spectrum of Chlamydial Infection Among Infants
Nearly two-thirds of the infants born vaginally to mothers with chlamydial infection
become infected during delivery (67,68 ). Even after ophthalmia prophylaxis with sil-
ver nitrate or antibiotic ointment, 15%–25% of infants exposed to chlamydia
developed chlamydia conjunctivitis, and 3%–16% developed chlamydia pneumonia
(41,68–73 ). C. trachomatis  is the most common cause of neonatal conjunctivitis
(72,74–78 ) and is one of the most common causes of pneumonia during the first few
months of life (79–85 ). Infants with chlamydia pneumonia are at increased risk for
abnormal pulmonary function tests later in childhood (86–88 ).
Clinical Spectrum of Chlamydial Infection Among Men
Although urethritis is the most common illness resulting from chlamydia, chlamy-
dial infections among men rarely result in sequelae. However, asymptomatic infected
men may unknowingly infect their sex partner(s) before seeking treatment.
Chlamydial infections among heterosexual men are usually urethral. Symptoms
are similar to gonorrhea (e.g., urethral discharge or dysuria). In contrast to gonorrheal
urethritis, chlamydia symptoms are often absent or mild (13–22,89 ). Therefore, the
number of heterosexual men with asymptomatic chlamydial infections is larger than
the number of such men with gonorrhea.
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Chlamydial infections of the lower genitourinary tract account for 30%–40% of the
4-6 million physician visits for nongonococcal urethritis (NGU), and 50% of the
158,000 outpatient visits and 7,000 hospitalizations for epididymitis among adolescent
and young adult males (2,3,90,91 ). Chlamydial infections among men readily respond
to treatment with antibiotics. Most of the morbidity and economic costs of chlamydial
infections among heterosexual men result from infection of female sex partners who
develop sequelae (3 ).
The rectum is a common site of initial chlamydial infection for men who engage in
receptive anal intercourse. Rectal infections are generally asymptomatic, but may
cause symptoms characteristic of proctitis (e.g., rectal discharge, pain during defeca-
tion) or proctocolitis (92–96 ).
Other Chlamydial Illnesses
Among adolescents and young adults of both sexes, chlamydial infection is an im-
portant part of the differential diagnosis for other, less common, illnesses. Chlamydia
salpingitis may progress to perihepatitis—the Fitz-Hugh-Curtis syndrome (97 ). Al-
though chlamydia is an uncommon cause of cystitis symptoms among female
patients, chlamydia has been an important cause of such symptoms in some groups
of young women who have pyuria, but sterile urine cultures (acute dysuria-pyuria syn-
drome or urethral syndrome) (5,38,98 ).
Another important, but uncommon complication of urogenital chlamydial infection
is Reiter’s syndrome (reactive arthritis, conjunctivitis, and urethritis), which occurs pri-
marily among men. Chlamydia is receiving greater emphasis in the differential
diagnosis of arthritis in young women because of the availability of diagnostic tests
for chlamydia. Chlamydial infection is more likely to be missed among women than
among men who have arthritis because of the less obvious role of urethritis.
Chlamydia is also part of the differential diagnosis of chronic conjunctivitis among
adolescents and young adults (99–102 ). Ocular or ophthalmic infections may result
from exposure to infectious genital secretions during oral-genital sexual contact, or by
autoinoculation. Although chlamydia can be detected in the pharynx after inoculation
from oral-genital exposure (103–111 ), chlamydia has not been established as a cause
of pharyngitis (103,104,110–114 ).
PREVENTION STRATEGIES 
The principal goal of chlamydia prevention strategies is to prevent both overt and
silent chlamydia salpingitis and its sequelae. Other goals include the prevention of
perinatal and postpartum infection and other adverse consequences of chlamydial in-
fection.
General Approach
The prevention of chlamydia salpingitis, pregnancy-related complications, and
other chlamydial illnesses requires that chlamydia prevention programs include both
primary and secondary prevention strategies.
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Primary Prevention Strategies
Primary prevention strategies are efforts to prevent chlamydial infection. Primary
prevention of chlamydia can be accomplished in two general ways.
• Behavioral changes that reduce the risk of acquiring or transmitting infection
should be promoted (e.g., delaying age at first intercourse, decreasing the num-
ber of sex partners, partner selection, and the use of barrier contraception
[condoms]). Efforts to effect behavioral changes are not specific  to chlamydia
prevention but are also critical components in preventing sexual transmission of
the human immunodeficiency virus (HIV) and other sexually transmitted dis-
eases (STDs) (45,115–117 ). 
• Identify and treat persons with genital chlamydial infection before they infect
their sex partners, and for pregnant women before they infect their babies. Ef-
forts to detect chlamydial infection are essential to chlamydia prevention.
Identifying and treating chlamydial infections require active screening and refer-
ral of sex partners of infected persons, since infections among women and men
are usually asymptomatic.
Secondary Prevention Strategies
Secondary prevention strategies are efforts to prevent complications among per-
sons infected with chlamydia. The most important complication to be prevented is
salpingitis and its potential sequelae (i.e., ectopic pregnancy, tubal infertility, and
chronic pelvic pain). Secondary prevention of chlamydia salpingitis can be accom-
plished by a) screening women to identify and treat asymptomatic chlamydial
infection; b) treating the female partners of men with infection; c) recognizing clinical
conditions such as mucopurulent cervicitis (MPC) and the urethral syndrome, and
then applying or using appropriate chlamydia diagnostic tests and treatment, as ap-
propriate.
Target Population
Chlamydial infection is especially prevalent among adolescents. Furthermore, PID
occurs more commonly after chlamydial infection among adolescent females than
among older women (42 ). Therefore, chlamydia prevention efforts should be directed
toward young women.
All sexually active adolescents and young adults are at high risk for chlamydia; the
infection is broadly distributed geographically and socioeconomically. Therefore,
chlamydia prevention programs should target all sexually active adolescents and
young adults. All private and public health-care providers should be involved in these
prevention efforts.
Specific Strategies
Specific strategies for the prevention of chlamydia are grouped into two categories.
Those categories are: a) community-based strategies, and b) health-care provider
strategies.
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Community-Based Strategies
Since the prevalence of chlamydia is consistently high among adolescents and
young adults regardless of socioeconomic status, race, or geographic location, pre-
vention efforts should be implemented communitywide.
Public Awareness. Community-based strategies should increase public awareness
of chlamydia, its consequences, and the availability and importance of diagnosis and
treatment. Groups at high risk for chlamydial infection and the persons who educate
and care for them (e.g., parents, teachers, and health-care providers) must be in-
formed about the high rate of genital chlamydial infection and its sequelae among
sexually active adolescents and young adults.
HIV/STD Risk Reduction Programs. Programs designed to reduce the risk of sexual
transmission of HIV and other STDs by means of behavioral changes should empha-
size the especially high risk of chlamydial infection. In addition, chlamydial infection
may be a sentinel for unsafe sexual practices. Concern about chlamydia may provide
additional motivation for persons to delay initiation of sexual activity, limit the number
of sex partners, avoid sex partners at increased risk for STDs, and use condoms.
Schools. Because of their access to adolescents, educators have an important role
to play in chlamydia prevention programs. Chlamydia-specific material should be in-
tegrated into educational curricula that address HIV and other STDs. In addition,
school programs should assist students in developing the social and behavioral skills
needed to avoid chlamydial infection, HIV, and other STDs.
Although most school health education curricula address HIV, fewer discuss other
STDs (including chlamydia). Information that should be provided through school
health education programs are listed below:
• Rates of chlamydial infection among adolescents
• Adverse consequences of chlamydia (e.g., PID and infertility)
• Symptoms and signs of chlamydial infection (and other STDs)
• Asymptomatic infection
• Treatment for sex partners
• Where and how to obtain health care (including locations, telephone numbers
[e.g., STD hot-line number], costs, and issues of confidentiality) 
Some schools may offer more than classroom instruction (e.g., access to health
care for infected persons and screening programs to identify asymptomatic chlamy-
dial infection). Personnel in school-based clinics that perform pelvic examinations
should use the opportunity to test for chlamydial infection. However, tests also are
needed to identify asymptomatic males (e.g., by screening urine collected during
sports physical examinations or other health-screening programs). The leukocyte
esterase test (LET) of urine is one possible method for testing males, but the accuracy
of the test requires additional evaluation (118 ). Such approaches to identifying and
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treating young men with asymptomatic chlamydial infection may prove important
since these persons may account for most of the transmission of chlamydia to young
women (see Laboratory Testing and Patient Care: An Expanded Role for the Use of
Chlamydia Tests).
Out-of-school Adolescents. The prevalence of chlamydia may be even greater
among adolescents who have dropped out of school. Therefore, organizations serving
these adolescents (e.g., Job Corps, vocational training centers, detention centers,
community-based recreational programs) should offer health care that addresses
chlamydial infection as part of STD/HIV risk reduction programs.
Health-Care Provider Strategies
Reducing the high prevalence of chlamydial infection requires that health-care
providers be aware of the high prevalence of chlamydia and recognize chlamydial
illness, screen asymptomatic patients, arrange for the treatment of sex partners, and
counsel all sexually active patients about the risks of STD infections. Medical provid-
ers should be trained to recognize and manage the following conditions that may be
caused by chlamydia: MPC, PID, urethral syndrome (women), and urethritis and
epididymitis (men).
Screening. The screening of women for chlamydial infection is a critical component
in a chlamydia prevention program since many women are asymptomatic, and the
infection may persist for extended periods of time. Many women of reproductive age
undergo pelvic examination during visits for routine health care or because of illness.
During these examinations, specimens can be obtained for chlamydia screening tests.
Female patients of adolescent-care providers, women undergoing induced abor-
tion, women attending STD clinics, and women in detention facilities should be
screened for chlamydial infection. Screening of these women is important because
a) many are adolescents or young adults, b) they are at high risk for salpingitis, and
c) they or their partners are likely to transmit infection.
Chlamydia screening at family planning and prenatal care clinics is particularly
cost-effective because of the large number of sexually active young women who un-
dergo pelvic examinations.
Providers such as family physicians, internists, obstetricians-gynecologists, and
pediatricians who provide care for sexually active young women also should imple-
ment chlamydia screening programs—although a lower volume of such patients may
increase the cost of testing. The following criteria can help identify women who
should be tested for chlamydia:
• Women with MPC
• Sexually active women <20 years of age
• Women 20–24 years of age who meet either of the following criteria, or women
>24 years of age who meet both criteria—inconsistent use of barrier contracep-
tion, or new or more than one sex partner during the last 3 months. 
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Patient selection criteria should be evaluated periodically. Although the incidence
of chlamydial infection among all women previously tested for chlamydia is unknown,
the incidence of chlamydial infection among previously infected adolescent females
has been as high as 39% (118 ). Because of the high incidence of chlamydial infection
among sexually active adolescent females, recommendations for the frequency of
testing are listed below:
• Women <20 years of age should be tested when undergoing a pelvic examina-
tion, unless sexual activity since the last test for chlamydia has been limited to a
single, mutually monogamous partner.
• All other women who meet the suggested screening criteria (listed above) should
be tested for chlamydia annually.
Although young men infrequently seek routine health care, medical providers
should use such opportunities to evaluate them for asymptomatic chlamydial infec-
tion, possibly by means of the LET (119 ) (see Laboratory Testing and Patient Care: An
Expanded Role for the Use of Chlamydia Tests).
Treatment of Sex Partners. Treatment of sex partners of infected persons is an im-
portant strategy for reaching large numbers of men and women with asymptomatic
chlamydial infection. Also, if partners are not treated, reinfection may occur. In addi-
tion, treating the male partners of infected women is critical since this is the principal
way to eliminate asymptomatic infection among males. If chlamydia screening is
widely implemented, the number of infected women identified may exceed the capac-
ity of some public health systems to notify, evaluate, and treat partners. Therefore,
health department personnel should assist health-care providers in developing coop-
erative approaches to refer partners for treatment. Where possible, health-care
providers who treat female patients for chlamydia should offer examination and treat-
ment services for the patients’ male sex partner(s), or should arrange the appropriate
referral of such partners.
Risk Reduction Counseling. In addition to screening, treatment, and referral of sex
partners(s) of persons with chlamydial infection, health-care providers should:
• Educate sexually active patients regarding HIV and other STDs,
• Assess the patients’ risk factors for infection,
• Offer at-risk patients advice about behavior changes to reduce the risk of infec-
tion,
• Encourage the use of condoms.
Preventing Chlamydial Infection During Pregnancy. To prevent maternal postnatal
complications and chlamydial infection among infants, pregnant women should be
screened for chlamydia during the third trimester, so that treatment, if needed, will be
completed before  delivery (see Primary Prevention Strategies). The screening criteria
already discussed can identify those at higher risk for infection. Screening during the
first trimester prevents transmission of the infection and adverse effects of chlamydia
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during the pregnancy. However, the evidence for adverse effects during pregnancy is
minimal. If screening is performed only during the first trimester, a longer period ex-
ists for infection before delivery.
Infants with chlamydial infections respond readily to treatment; morbidity can be
limited by the early diagnosis and systemtic treatment of infants who have conjuncti-
vitis and pneumonia caused by chlamydial infection (secondary prevention
strategies). Further, the mothers of infants diagnosed with chlamydial infection and
the sex partner(s) of those mothers should be evaluated and treated.
LABORATORY TESTING
Diagnostic test manufacturers have introduced a variety of nonculture tests for
chlamydia, including enzyme immunoassays (EIAs) to detect chlamydia antigens,
fluorescein-conjugated monoclonal antibodies for the direct visualization of chlamy-
dia elementary bodies on smears, nucleic acid hybridization tests, and rapid (stat)
tests. Because nonculture tests do not require strict handling of specimens, they are
easier to perform and less expensive than culture tests; consequently the numbers of
laboratories and health-care providers offering chlamydia testing have increased. The
expanded use of nonculture tests is a cornerstone of chlamydia prevention strategies.
Although nonculture tests have advantages that make them more suitable than cell
culture tests for widespread screening programs, nonculture tests also have limita-
tions. In particular, nonculture tests are less specific than culture tests and may
produce false-positive results. All positive nonculture results should be interpreted as
presumptive  infection until verified by culture or other nonculture test. The decision
to treat and perform additional tests should be based on the specific clinical situation.
The test methodologies discussed in these recommendations are for the detection
of Chlamydia trachomatis —not other chlamydia species (e.g., C. psittaci  and C. pneu-
moniae ). A number of commercial products for the detection of C. trachomatis  are
available; however, most information relating to the performance of most of these
products is the manufacturers’ data. When possible, health-care providers and labora-
tory staff should compare a potential nonculture test’s performance with that of an
appropriate standard in their own laboratory.
Specimens for Screening
The proper collection and handling of specimens are important in all the methods
used to identify chlamydia. Even diagnostic tests with the highest performance rat-
ings cannot produce accurate results when specimens submitted to the laboratory are
improperly collected. Clinicians require training and periodic assessment to maintain
proper technique.
Because chlamydia are obligate intracellular organisms that infect the columnar
epithelium, the objective of specimen collection procedures is to obtain columnar epi-
thelial cells from the endocervix or the urethra. The following recommendations for
specimen collection apply to all screening tests.
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Preferred Anatomic Sites
The endocervix is the preferred anatomic site to collect screening specimens from
women. When culture isolation is to be used, processing an additional specimen from
the urethra may increase sensitivity by 23% (120 ). Placing the two specimens in the
same transport container is acceptable. For nonculture tests, the usefulness of a sec-
ond specimen from the urethra has not been determined.
The urethra is the preferred site for collecting screening specimens from men.
Collecting Specimens
The following guidelines are recommended for obtaining endocervical specimens:
• Obtain specimens for chlamydia tests after obtaining specimens for gram-
stained smear, Neisseria gonorrhoeae  culture, or Papanicolaou smear.
• Before obtaining a specimen for a chlamydia test, use a sponge or large swab to
remove all secretions and discharge from the cervical os.
• For nonculture chlamydia tests, use the swab supplied or specified by the manu-
facturer of the test.
• Insert the appropriate swab or endocervical brush 1–2 cm into the endocervical
canal (i.e., past the squamocolumnar junction). Rotate the swab against the wall
of the endocervical canal several times for 10–30 seconds. Withdraw the swab
without touching any vaginal surfaces and place it in the appropriate transport
medium (culture, EIA, or deoxyribonucleic acid [DNA] probe testing) or prepare a
slide (direct fluorescent antibody [DFA] testing).
The following guidelines are recommended for obtaining urethral specimens:
• Delay obtaining specimens until 2 hours after the patient has voided.
• Obtain specimens for chlamydia tests after obtaining specimens for gram-stain
smear or N. gonorrhoeae  culture.
• For nonculture chlamydia tests, use the swab supplied or specified by the manu-
facturer.
• Gently insert the urogenital swab into the urethra (females: 1–2 cm, males: 2–4
cm). Rotate the swab in one direction for at least one revolution for 5 seconds.
Withdraw the swab and place it in the appropriate transport medium (culture,
EIA, or DNA probe testing) or use the swab to prepare a slide for DFA testing.
Quality Assurance of Specimen Collection
Without specimen quality assurance, ≥10% of specimens are likely to be unsatisfac-
tory because they contain secretions or exudate, but lack urethral or endocervical
columnar cells (6,121–122 ). Periodic cytologic evaluation of specimen quality is re-
commended when using non-DFA tests to ensure continued proper specimen
collection.
10 MMWR August 6, 1993
Cell Culture
Compared with other diagnostic tests for C. trachomatis, a major advantage of cell
culture isolation is a specificity that approaches 100%. In cell culture, organisms from
each of the three chlamydia species (C. trachomatis, C. pneumoniae, C. psittaci ) grow
and produce intracytoplasmic inclusions. The direct visualization of these inclusions
contributes to the specificity of cell culture in identifying chlamydia. The preferred
method for identifying inclusions is to stain the infected cells with a species-specific,
monoclonal fluorescein-labeled antibody (FA) for C. trachomatis. Alternative antibod-
ies used to stain chlamydia inclusions that bind to chlamydia lipopolysaccharide (LPS)
are NOT specific for C. trachomatis and also will stain C. psittaci  and C. pneumoniae 
inclusions. In these recommendations, the use of C. trachomatis-specific, anti-major
outer membrane protein (MOMP) antibody is the presumed method used for the de-
tection of C. trachomatis  isolated in cell culture.
Culture sensitivity is approximately 70%–90% in experienced laboratories (123 ).
Since culture amplifies small numbers of organisms, it is preferred for specimens in
which low numbers of organisms are anticipated (e.g., asymptomatic infection). Cul-
ture also allows the organism to be preserved for additional studies, including the
determination of immunotype (serovar) and antimicrobial susceptibilities.
Cell culture isolation has several disadvantages. First, the method is technically dif-
ficult and requires 3–7 days to obtain a result. Second, since only viable organisms are
detected, special transport media must be used, and transportation and storage tem-
perature requirements are stringent. Finally, some specimens contain contaminating
microorganisms or substances that are toxic to the cell monolayers used for isolating
chlamydia.
Indications for the Use of Cell Culture
A high-quality culture system for chlamydia is the diagnostic method of choice and
is essential for the diagnosis of chlamydia in all medical/legal situations.
Culture serves as the standard for the quality assurance of nonculture tests and for
the evaluation of new diagnostic methods. Culture is recommended for detection of
chlamydia in specimens for which nonculture methods have not been developed,
have not been adequately evaluated, or perform poorly. Culture is recommended for
specimens from the following sites:
• Urethral specimens (women and asymptomatic men).
• Nasopharyngeal specimens (infants).
• Rectal specimens (all patients, regardless of age).
• Vaginal specimens (prepubertal girls).
Collecting Specimens for Cell Culture
Swabs with plastic or wire shafts can be used to obtain cell cultures. Swab tips can
be made of cotton, rayon, dacron, or calcium alginate. Swabs with wooden shafts
should not be used because the wood may contain substances that are toxic to
chlamydia. As part of routine quality control, samples of each lot of swabs that are
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used to collect specimens for chlamydia isolation should be screened for possible tox-
icity to chlamydia.
The substitution of an endocervical brush for a swab may increase the sensitivity of
culture for endocervical specimens from nonpregnant women (124 ). However, the
use of the endocervical brush may induce bleeding. Although such bleeding does not
interfere with the isolation of C. trachomatis, patients should be advised about possi-
ble spotting. 
Transporting Cell Culture Specimens
The viability of chlamydia organisms must be maintained during transport to the
laboratory. Consult with the laboratory regarding the selection of appropriate trans-
port medium and procedures (125,126 ). Specific recommendations for transporting
specimens are listed below:
• Specimens for culture should be stored at 4 C and inoculated in cell culture as
quickly as possible after collection. The elapsed time until inoculation should not
exceed 24 hours. If specimens cannot be inoculated within 24 hours, the speci-
mens should be maintained at -70 C or colder. 
• Specimens for culture should never be stored at -20 C or in “frost-free” freezers.
These conditions cause a decrease in chlamydia viability.
Analyzing Cell Culture Specimens
Cycloheximide-treated McCoy cells are commonly used to culture chlamydia. Dif-
ferent McCoy cell lines exist and some have reduced susceptibility to chlamydial
infection. McCoy cells are available commercially and from the American Type Culture
Collection. Specific recommendations for analyzing specimens include the following
are listed below (125,126 ):
• Only cell lines that have been checked for their ability to support chlamydial
growth should be used.
• The identification of C. trachomatis  should be based on visualizing characteristic
chlamydia inclusions using species-specific FA staining.
• Laboratories should determine periodically whether multiple passages will in-
crease sensitivity.
NOTE: The specificity of culture is based on the identification of inclusions. The
identification of chlamydia after culture by EIA, or any other method that does not
identify characteristic intracytoplasmic inclusions, is NOT recommended.
Interpreting Cell Culture Results
A positive cell culture and visualization of characteristic inclusions by species-spe-
cific monoclonal FA staining is required to diagnose a chlamydial infection. With
proper technique, the specificity of cell culture isolation of C. trachomatis  is nearly
100%.
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A negative chlamydia culture does not rule out the presence of a chlamydial infec-
tion. The sensitivity of culture is approximately 70%–90% when recommended
laboratory and specimen collection techniques are performed.
Quality Assurance of Cell Culture Specimen Collection
The isolation and detection of chlamydia in cell culture are technically demanding.
The training of clinicians and laboratorians, along with quality assurance of laboratory
performance and specimen collection, is critical to performing cell culture adequately.
Specific recommendations to follow for cell culture specimens are listed below:
• To monitor the sensitivity and specificity of the cell culture system, laboratories
should include known samples to analyze appropriate positive and negative con-
trols when clinical specimens are cultured.
• Periodically (i.e., monthly or bimonthly), positive controls should be submitted
from patient settings to verify the effectiveness of transport systems.
• Reference laboratories should provide a quality assurance system for monitoring
culture performance and specimen adequacy. These laboratories also should
provide assistance in the evaluation of unexpected or discrepant results.
Educational materials developed by CDC are available through the National Labo-
ratory Training Network for the training of laboratory personnel who perform cell
culture isolation of C. trachomatis (CDC, Public Health Practice Program Office, Divi-
sion of Laboratory Systems, Laboratory Practice Training Branch, 1600 Clifton Road,
MS A-16, Atlanta, GA 30333). Clinical training in genital examinations, including cor-
rect specimen collection techniques, is available through CDC’s Sexually Transmitted
Diseases Prevention/Training Centers (CDC, National Center for Prevention Services,
Division of STD/HIV Prevention, Training and Education Branch, 1600 Clifton Road, MS
E-27, Atlanta, GA 30333).
Nonculture Chlamydia Tests
More aggressive prevention strategies are now possible with the availability of
nonculture test methods for the detection of chlamydia. Published evaluations of the
performance of nonculture chlamydia tests are based primarily on the MicroTrak® DFA
(Syva) test and the Chlamydiazyme® EIA (Abbott) test. Additional tests have been ap-
proved by the FDA for the detection of chlamydial infection. Published information on
these other tests is increasing rapidly, but is still limited. The recommended uses of
nonculture chlamydia tests for presumptive diagnosis, with and without additional
testing, to verify a positive result are summarized in these recommendations (Table 1).
Description of Nonculture Tests
Nonculture chlamydia tests include several categories that differ in format and exe-
cution.
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Direct Fluorescent Antibody (DFA) tests. Depending on the commercial product used,
the antigen that is detected by the antibody in the DFA procedure is either the MOMP
or LPS. Specimen material is obtained with a swab or endocervical brush which is
then rolled over the specimen “well” of a slide. After the slide has dried and the fixa-
tive has been applied, the slide can be stored or shipped at ambient temperature. The
slide should be processed by the laboratory within 7 days after the specimen has been
obtained. Staining consists of covering the smear with fluorescent monoclonal anti-
body that binds to chlamydia elementary bodies. Stained elementary bodies are then
identified by fluorescence microscopy. Total processing time is 30–40 minutes. Only
C. trachomatis  organisms will stain with the anti-MOMP antibodies used in commer-
cial kits. Cross-reactions can occur between the anti-LPS antibodies used in
commercial kits and other bacterial species, as well as with C. pneumoniae  and
C. psittaci.
Enzyme Immunoassay (EIA) Tests. EIA tests detect chlamydia LPS with a monoclonal
or polyclonal antibody that has been labeled with an enzyme. The enzyme converts a
colorless substrate into a colored product. The intensity of the color is measured with
a spectrophotometer, which provides a numerical readout. The specimens for EIA are
collected by using specimen collection kits supplied by the manufacturer. These kits
include swabs, transport tubes, and instructions (to obtain optimum performance of
the test kit, manufacturer’s instructions should be followed). Specimens can be stored








Women Cervical High No† Yes§
High Yes With verification§
Low Yes or No With verification§¶
Men Urethral High (symptomatic) No Yes**
Yes With verification**
Low (asymptomatic) Yes or No Insufficient data
Women
and men Rectal Any Yes or No No
Infants Genital/rectal Any Yes or No No
Nasopharyngeal Any Yes or No No
Conjunctival Any Yes or No   Yes††
 *High=≥5%.
†Includes adverse effects for a patient being misdiagnosed as having a sexually transmitted
chlamydial infection.
§Includes the following tests: Chlamydiazyme®EIA, IDEIA®, Pace 2®, MicroTrak® DFA, and
MicroTrak® EIA. Other tests cannot be recommended because of insufficient data.
¶Chlamydia tests in low-prevalence patient populations have not been extensively evaluated.
**Includes the following tests: Chlamydiazyme® and MicroTrak® DFA. Other tests cannot be
recommended because of insufficient data.
††In a limited number of evaluations, nonculture test performance with conjunctival specimens
has been at least as good as with genital specimens.
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and transported at ambient temperature and should be processed within the time in-
dicated by the manufacturer. Total processing time is 3–4 hours.
One disadvantage of the EIA methods that detect LPS is that cross-reaction of the
antibody with other microorganisms leads to false-positive results (125,127–129 ). In
addition, the LPS-based EIA tests detect all three chlamydia species and, therefore, are
not specific for C. trachomatis. Some manufacturers have developed blocking assays
that are used to verify positive EIA test results. The test is repeated on initially positive
specimens with the addition of a monoclonal antibody specific for chlamydia LPS. The
monoclonal antibody competitively inhibits chlamydia-specific binding by the en-
zyme-labeled antibody; a negative result with the blocking antibody is interpreted as
verification of the initial positive test result.
Nucleic Acid Hybridization Tests (DNA Probe). Nucleic acid hybridization methods can
be used for the diagnosis of chlamydial infections. In the hybridization assay, a chemi-
luminescent DNA probe that is complimentary to a specific sequence of
C. trachomatis  ribosomal RNA (rRNA) is allowed to hybridize to any chlamydia rRNA
that is present in the specimen. The resulting DNA:rRNA hybrids are adsorbed to mag-
netic particles and are then detected by using a luminometer that provides a
numerical readout. The test kit includes a specimen collection swab and transport me-
dium. Specimens should be maintained at temperatures of 2–25 C during transport
and storage. The manufacturer suggests that assays be performed within 7 days after
collection; otherwise the specimens should be stored at -20 C or colder. Total process-
ing time is 2–3 hours.
The technical requirements and the necessary expertise to perform nucleic acid
hybridization tests are similar to those of the EIA methods. The probe assay is specific
for C. trachomatis; cross-reactions with organisms other than C. trachomatis, includ-
ing C. pneumoniae  and C. psittaci, have not been reported. A competitive probe assay
has been developed to provide a means of assuring high specificity. The usefulness of
the competitive assay is being evaluated in clinical trials and has not been approved
for in vitro use by the Food and Drug Administration (FDA).
Rapid Chlamydia Tests. Chlamydia tests have been developed that can be performed
within 30 minutes, do not require expensive or sophisticated equipment, and are pack-
aged as single units. The results are read qualitatively. These rapid or stat tests can
offer advantages in physicians’ offices, small clinics and hospitals, and settings in
which results are needed immediately (e.g., when making decisions about additional
testing or treatment while the patient is still present). Like EIAs, these tests use anti-
bodies against LPS that detect all three chlamydia species, but are subject to the same
potential for false-positive results due to cross-reactions with other microorganisms.
The performance characteristics of these tests have not been extensively evaluated. In
addition, since rapid chlamydia tests are designed to be performed by nonlaboratory
personnel, quality assurance is essential. Personnel requirements, quality assurance,
and quality control requirements relating to the use of these and other tests are pub-
lished in the Clinical Laboratory Improvement Amendments (CLIA) (130 ) and are
governed by the test categorization compilation.
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Leukocyte Esterase Test (LET). The LET is a dipstick test that is applied to urine speci-
mens to screen for urinary tract infection. The LET detects enzymes that are produced
by polymorphonuclear leukocytes. These enzymes hydrolyze an indoxylcarbonic acid
ester on the dipstick to indoxyl, which reacts with an indicator in the strip to produce
a purple color. The procedure requires <2 minutes to perform after the specimen is
collected.
Accuracy of Nonculture Tests and Recommendations for Use
For small-volume testing, DFA may be preferred because the quality of the speci-
men can be assessed. Automated tests are probably preferable for high-volume
testing, but a quality control system is essential for monitoring the adequacy of speci-
mens.
Published evaluations of the performance of nonculture chlamydia tests are based
primarily on the MicroTrak® DFA (Syva) test and the Chlamydiazyme® EIA (Abbott)
test. Additional tests have been approved by the FDA for the detection of chlamydial
infection. Published information on these other tests is increasing, but is still limited.
Cervical Specimens from Women (Sensitivity). The performance characteristics of Mi-
croTrak® DFA and Chlamydiazyme® nonculture chlamydia tests have been reported in
published evaluations of women in high-prevalence (≥5%) patient populations. Sensi-
tivities, using culture as a standard, have varied greatly but generally exceed 70%
(CDC, unpublished review ). This variability in reported sensitivity is a result of differ-
ences in specimen collection technique, performance of the culture system used as a
standard, and patient characteristics (e.g., age, MPC, and other factors such as preva-
lence of chlamydial infection, duration of infection, and previous exposure to
chlamydia) (121,122,128,131–136 ). A sensitivity of at least 70% is adequate for screen-
ing, but not sufficient to exclude chlamydial infection (see Patient Care: An Expanded
Role for the Use of Chlamydia Tests).
Evaluations have been presented or published for the use of a number of tests for
cervical specimens from women. Such tests include IDEIA® (Dako Diagnostics), Pace
2® (Gen-Probe), MicroTrak® EIA (Syva), and Clearview® (Unipath) tests. Sensitivities
reported for these tests are comparable to sensitivities reported for Chlamydiazyme®
and MicroTrak® DFA. However, chlamydia diagnostics experts recommend additional
evaluation of these tests. First, the true sensitivity of these tests may be less than that
indicated in published reports. The number of evaluations published for any given test
is small and the number of patients with chlamydial infections studied in most evalu-
ations is also small. Therefore, sensitivities may prove to be lower (or higher) as more
evaluations are reported. More evaluations need to be conducted by laboratories that
have quality assurance programs for culture including, for example, exchange of
specimens with other laboratories (proficiency testing). Evaluations that compare new
tests directly with established tests would aid in determining the performance of new
tests. Second, none of these tests have been adequately evaluated in low-prevalence
patient populations. Diagnostics experts are concerned that differences in factors
such as previous exposure to chlamydia and duration of infection may result in lower
test sensitivities in low-prevalence populations (128 ). Third, although the reported
performance of the Clearview® rapid (stat) test approaches that of Chlamydiazyme®
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and MicroTrak® DFA, additional evaluations are needed to determine its performance
when the test is used in an outpatient setting during the patient’s visit. Too few evalu-
ations have been reported for other chlamydia tests to assess their sensitivities
(≤3 patient care-laboratory settings or 240 patients with chlamydia isolated by cell cul-
ture).
Specificity and Predictive Value Positive. The specificity of nonculture tests for cer-
vical specimens has been high (97%–99%). However, clinicians should be aware that
even with these high specificities, false positive results account for an important pro-
portion of all positive test results among groups of patients with a low prevalence of
chlamydial infection. The effect of false-positive tests in a population can be quantified
by the predictive value positive (PVP). The PVP is the proportion of all persons who
have a positive test result for a condition who actually have that condition. In chlamy-
dia screening applications, the PVP is influenced primarily by the specificity of the test
and the prevalence of chlamydia. For example, when a nonculture test with a specific-
ity of 98% and a sensitivity of 80% is used to screen 1,000 patients from a high-risk
patient population with a chlamydia prevalence of 15% (150 patients have an infec-
tion), the test produces 137 positive results: 120 patients are actually infected and
17 are not infected (false-positives). The PVP is 120/137=0.88. When this same test is
used to screen 1,000 patients from a low-risk patient population with a chlamydia
prevalence of only 2% (20 patients have an infection), 36 positive results are obtained:
16 patients are infected and 20 are not. The PVP is 16/36=0.44. In the low-risk patient
population, fewer than half the patients with positive tests actually have chlamydial
infection; the remainder are at risk of being incorrectly identified as having an STD
unless the clinician takes other measures, such as arranging for verification when
screening results are positive. 
Specificities of the nonculture tests have been <99% in most published evaluations
even when a third test was used to detect false-negative cultures. Contamination of
cervical specimens with vaginal secretions is responsible for some false-positive tests
when using Chlamydiazyme. The polyclonal anti-LPS antibody used in Chlamy-
diazyme crossreacts with LPS on other bacteria found in the vagina and urinary tract
of these patients (121,122,125,127,128,137 ). The source of nonspecific fluorescence
with MicroTrak® DFA and of nonspecific signals with tests using monoclonal antibod-
ies or genetic probes has not been determined. NOTE: Hereafter, a prevalence of
<5% is considered to be “low prevalence.” At a 5% prevalence (specificity 99% and
sensitivity 80%), the PVP would be 80%. Although defining low prevalence as <5% is
arbitrary, the potential for 20% of positive test results to be falsely positive (in the
absence of a second test for verification) supports the utility of this cutoff.
Verifying Positive Screening Test Results. Clinicians should verify positive screen-
ing test results with a supplemental test if a false-positive test result is likely to have
adverse medical, social, or psychological consequences (Table 1). Verification should
probably be routine in low-prevalence patient populations, but might be selective in
high-prevalence populations. Methods that are suitable for verifying positive noncul-
ture tests for cervical specimens are recommended below:
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• Verify positive tests by culture, using fluorescein-conjugated C. trachomatis-
specific antibody. Culture is the most sensitive and specific method for verifica-
tion. However, verification with culture requires a second specimen that is
collected either at the time the first specimen is collected or during a return visit.
Because of the limited availability of culture testing and the requirement for a
second specimen, culture should be used for verification only if very high speci-
ficity is required (e.g., medical/legal situations).
• Perform a second nonculture test that identifies a C. trachomatis  antigen or a
nucleic acid sequence that is different from that identified by the screening test.
Theoretically, detecting a second, highly specific antigen or nucleic acid se-
quence should provide adequate specificity for verification. However, this
approach has had limited evaluation in field trials. A positive screening test may
be verified by a second test using a second specimen that is collected either at
the time the first specimen is collected or during a return visit. To avoid taking a
second specimen, some EIA test manufacturers suggest using the excess speci-
men in the EIA transport medium for verification of positive EIA tests with a DFA
test.
• Use an unlabeled “blocking” antibody or “competitive” probe that verifies a
positive test result by preventing attachment of the labeled antibody or probe
that is used in the standard assay. These methods are theoretically less desirable
because they identify the same molecules as those identified by the initial non-
culture tests. However, the Chlamydiazyme® blocking antibody test appears to
produce adequate results (127,138–142 ). These methods do not require collect-
ing a second specimen.
With the exception of the Chlamydiazyme® blocking antibody test, nonculture
methods of verifying initial positive chlamydia test results have received insufficient
evaluation. Since the sensitivity of tests used for verification of positive chlamydia
tests is uncertain but <90%, failure to verify the initial positive test does not rule out
chlamydial infection. Evaluation studies are needed to determine which of the above
approaches is preferable in relation to sensitivity, specificity, and cost (see Clinician-
Laboratory Protocols for Verifying Positive Tests).
Urethral Specimens from Men. The use of the Chlamydiazyme® EIA test and the Mi-
croTrak® DFA test for urethral specimens from males with symptomatic urethritis has
been evaluated in published studies. Reported sensitivities of the Chlamydiazyme®
EIA and MicroTrak® DFA tests among men with chlamydial urethritis have been highly
variable but usually exceed 70%. These sensitivities are sufficiently high to recom-
mend using these tests to detect chlamydial infections among men with symptomatic
urethritis. In such men, detection of chlamydial infection may be useful in promoting
examination and treatment of sex partners and managing the patient’s infection. Nei-
ther nonculture tests nor tissue culture isolation are sufficiently sensitive to rule out
chlamydial infection based solely on a negative test result.
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Positive Chlamydiazyme® and MicroTrak® DFA tests have been highly predictive of
chlamydial infection among adolescent and young adult men with symptomatic ure-
thritis. The reported specificities of the Chlamydiazyme® EIA and MicroTrak® DFA
tests for urethral specimens from men with symptomatic urethritis have been suffi-
ciently high (97%–≥99%). Because Chlamydiazyme® may yield false-positive results
from the urine of men with bladder infections, a positive nonculture test result may be
less predictive of chlamydial infection among older men who have a higher incidence
of nonchlamydial urinary tract infection (143 ).
Because information on the performance of the nonculture tests among asympto-
matic men is limited and tests for identifying asymptomatic urethral infection among
men may be insensitive, none of the nonculture tests are recommended for this group
of patients.
Other Nonculture Test Specimens 
Urine. The LET can be used to screen sexually active teenage males for urethritis,
which is often caused by chlamydia or gonorrhea. Patients with positive results indi-
cating the presence of urethritis require specific tests for C. trachomatis  and
N. gonorrhoeae. Reported sensitivities of the LET in screening for chlamydia and
gonorrhea range from 46% to 100% and specificities range from 83% to 100%
(19,20,144,145 ). Data are insufficient to recommend its use for older males or for
women.
Rectum. Culture is the preferred method for detecting chlamydia in rectal specimens.
Some DFA reagents have been approved by the FDA to evaluate rectal specimens;
however, the specificity of the test for rectal specimens may be less than that for speci-
mens from the cervix or the urethra. If DFA is used, slides should be read only by
highly experienced microscopists.
Conjunctiva. Although data are limited, the performance of nonculture tests with con-
junctival specimens has been at least as effective as with genital specimens.
Nasopharynx (Infants). Nonculture tests have not been adequately evaluated for the
detection of C. trachomatis  in nasopharyngeal specimens. Many of these tests cannot
distinguish between C. trachomatis, C. pneumoniae, or C. psittaci.
Serum. Chlamydia serology has little value in the routine clinical care of genital tract
infections. Commercial serologic tests are not useful in routine diagnosis because pre-
vious chlamydial infections elicit long-lasting antibodies that cannot be easily
distinguished from the antibodies produced in a current infection.
Immunoglobulin M microimmunofluorescence (MIF) is the test used frequently for
the diagnosis of chlamydial pneumonia among infants. Chlamydia serology is also
useful for persons with symptoms consistent with lymphogranuloma venereum
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(LGV). For such persons, a fourfold rise in MIF titer to LGV antigens or a complement
fixation titer of ≥1:32 supports a presumptive diagnosis of LGV. The difficulties in pre-
paring antigens and in performing these tests restrict their use to a limited number of
reference and research laboratories.
Post-Treatment Tests. If a post-treatment test is performed using a nonculture test, the
test should be scheduled a minimum of 3 weeks after completion of antimicrobial
therapy. Tests performed earlier may be false-negative because of small numbers of
chlamydia organisms; the presence of dead organisms also causes false-positive non-
culture test results (see Follow-up of Patients Treated for Chlamydial Infection).
Quality Assurance of Nonculture Tests
As more laboratories begin to provide diagnostic services for chlamydial infec-
tions, the development of an infrastructure for laboratory quality assurance is
increasingly important. Sites in which laboratory testing is performed must adhere to
the CLIA regulations for staffing, professional training, patient test management, qual-
ity assurance, and quality control (130 ). Federal and state regulatory agencies that
monitor quality assurance and quality control may have additional requirements and
should be consulted for specific information.
Each laboratory should verify the accuracy of nonculture test methods by peri-
odically comparing its results with those obtained by using a high-quality culture
system. In addition, CLIA recommends that laboratories enroll in proficiency testing
programs, such as those provided by the College of American Pathologists and the
American Proficiency Institute. These quality assurance measures are especially im-
portant when a laboratory implements a new test method.
Training is recommended for the performance of all laboratory tests for chlamydia.
Sources of training include product manufacturers, the National Laboratory Training
Network (a source of instructional material that also may assist in locating or co-
sponsoring training workshops), and individual state public health laboratories.
All clinicians, particularly new providers of chlamydia testing services, should be
trained in order to obtain adequate specimens. This training should include a) instruc-
tion in obtaining sufficient numbers of cells from any particular site, and b) instruction
in obtaining endocervical cells rather than ectocervical cells or vaginal material from
the cervix.
Laboratory Testing for Sexual Assault and Abuse Victims
Detailed information concerning the evaluation and treatment of suspected victims
of sexual assault or abuse may be obtained from the 1993 Sexually Transmitted Dis-
eases Treatment Guidelines  (146 ) and the Sexually Transmitted Diseases Clinical
Practice Guidelines 1991  (147 ).
Specimens that are taken for chlamydia testing immediately after sexual assault
may yield false-negative results because of small numbers of organisms present early
in infection. Also, tests may be positive because of prior — not assault-acquired —
infection. Specimens for chlamydia cultures should be obtained from adults and ado-
lescents during the initial evaluation and at a follow-up visit 2 weeks later. Specimens
should be obtained from all sites of exposure.
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Among children, specimens should be routinely collected from the pharynx and the
rectum in addition to the vagina (girls). In the absence of signs of urethral infection,
obtaining a urethral specimen from boys may not be justified because of a relatively
low yield of positive test results and the discomfort associated with obtaining the
specimen. The decision to obtain specimens at a follow-up examination must be de-
termined according to each case. Obtaining such follow-up specimens may not be
justified if the exposure occurred several days or more before the initial examination,
or if the examination would be psychologically traumatic.
Only cell culture isolation using standard methods employing C. trachomatis-
specific antibodies should be used to detect C. trachomatis  infection in the investiga-
tion of possible sexual abuse (129 ). Nonculture tests are not sufficiently sensitive or
specific to be used in the investigation of sexual abuse (129,138,148–151 ). All speci-
mens and isolates from both suspected victims and alleged assailants should be
stored at -70 C or colder in case additional testing by a qualified reference laboratory
is needed.
Future Directions for Laboratory Testing
The availability of sensitive and noninvasive C. trachomatis-specific screening tests
for men and women (e.g., urine tests) will greatly expand the population that can be
screened. For women, such tests are not now available. For men, sensitivities for EIA
methods for detecting chlamydia in first-voided urine range from 30% in a group of
asymptomatic men (152 ) to approximately 88% in men with symptoms (153 ). Al-
though specificity is ≥97%, increased rates of false-positive results have been reported
with specimens from men with urinary tract infections caused by Escherichia coli  and
Klebsiella pneumoniae (143 ). Further studies are needed before noninvasive
C. trachomatis  screening tests for asymptomatic men can be recommended.
Recent evidence suggests that the numerical results of nonculture tests, together
with the cutoff point for a positive result, might aid laboratories and clinicians in deter-
mining when to perform a second test to verify the initial results (139,154 ). Positive
results that substantially exceed the cutoff point may be more likely to be true posi-
tives than those near the cutoff point. Similarly, negative results that are close to the
cutoff point may be less likely to be true negatives than those with lower values. By
establishing a zone just above and just below the cutoff, specimens giving low-posi-
tive or high-negative results would be evaluated by a second test. The desired effect
would be to increase both the sensitivity and specificity of tests. Although studies are
in progress, data are insufficient for a formal recommendation on the use of numerical
results.
Technologies will continue to be refined, thereby improving both the sensitivity and
the specificity of available tests for sexually transmitted chlamydial infections. Be-
cause of their ability to amplify chlamydia DNA in the specimen, new technologies
such as polymerase chain reaction (CPCR) and ligase chain reaction (LCR) promise
specificities equal to, and sensitivities higher than, those of culture.
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PATIENT CARE: AN EXPANDED ROLE FOR
THE USE OF CHLAMYDIA TESTS
The Chlamydia trachomatis  infections policy guidelines published in 1985 (1 ) em-
phasized the need to include treatment for chlamydia in regimens for patients whose
diagnoses were strongly associated with chlamydial infection. The increasing avail-
ability of accurate and economical chlamydia tests permits widespread screening of
asymptomatic persons, but also suggests that chlamydia treatment for symptomatic
patients and the referral of sex partners in the absence of testing, a key strategy in past
guidelines, should be discouraged. These tests should be used to diagnose chlamydia
for patients with symptoms or signs suggestive of chlamydial infection even if therapy
is administered and partners are referred before test results are available. A specific
chlamydia diagnosis should facilitate sex partner referral since a positive chlamydia
test result indicates that the patient’s infection is sexually transmitted. A specific diag-
nosis may also facilitate medical care for patients who do not respond as expected to
initial chlamydia therapy.
Some providers do not have resources to screen asymptomatic patients for
chlamydia and to also test patients whose conditions warrant presumptive treatment
and partner referral. If presumptive treatment of patients with symptoms or signs of
chlamydia without testing is elected, efforts must be made to ensure the treatment of
partners.
Although the benefits of chlamydia tests for screening and diagnosis justify their
use, the potential for adverse consequences must also be recognized and steps taken
to minimize them. The adverse consequences for infected patients and their sex
partners, including disease complications and transmission of chlamydial infection,
may occur if chlamydia treatment is delayed while waiting for test results or if treat-
ment is withheld because of a false-negative test result. Adverse consequences also
may occur if uninfected patients and their sex partners are treated unnecessarily be-
cause the chlamydia test result is unavailable or false-positive. The adverse
consequences of treating uninfected persons are more likely to be psychosocial, re-
sulting from the misdiagnosis of a sexually transmitted infection; adverse effects of
the antibiotic used to treat chlamydia are relatively uncommon and mild.
These adverse consequences can be avoided by a) treating patients who are symp-
tomatic or have a substantially increased risk of chlamydial infection and treating their
sex partners for chlamydia without waiting for chlamydia test results, and b) arrang-
ing for a second test to verify an initial positive screening test result for patients and
their sex partners who are susceptible to the adverse psychosocial consequences of
having a false diagnosis of an STD. 
Presumptive Diagnosis of Chlamydial Infection
Several conditions—NGU, PID, epididymitis, and gonococcal infection—are consis-
tently associated with an increased prevalence of chlamydial infection among patients
and their sex partners (Table 2). Patients with these illnesses require immediate treat-
ment to relieve symptoms and/or to prevent complications. Treatment for these
conditions should include an antibiotic regimen for chlamydia. Sex partners of in-
fected patients should be evaluated and treated for chlamydia without waiting for the
patient’s test results.
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Immediate chlamydia treatment of MPC is warranted by an increased prevalence of
chlamydia among women with this condition in most patient care settings. However,
immediate chlamydia treatment of MPC or urethral syndrome among females or proc-
titis among homosexual males—and the referral of sex partners of patients with any
of these conditions before obtaining a microbiologic diagnosis—may not always be
warranted (Table 3). Chlamydia risk factors (e.g., age <25 years, having new or multi-
ple sex partners) and the likelihood of compliance with follow-up visits should be
considered when deciding whether to defer chlamydia treatment and referral of sex
partners until chlamydia test results are available. Whenever possible, these decisions
should be based on local estimates of chlamydia prevalence.
Chlamydia Tests for Patients Who Are Treated Presumptively
Even if a patient with a presumptive diagnosis of chlamydial infection will be
treated and counseled to refer partners before test results are known, chlamydia tests
should be performed:
• Ensuring appropriate medical care, particularly if symptoms persist,
• Facilitating counseling of the patient,
• Providing firm grounds for partner notification,
• Improving compliance.
Limited resources may require health-care providers to decide between performing
chlamydia tests for patients who would be treated for chlamydia because of symp-
toms or signs and patients who are asymptomatic and would not otherwise receive
chlamydia treatment. If the health-care provider elects to provide presumptive treat-
ment for patients with symptoms or signs—but without chlamydia testing—efforts
must be made to ensure treating the sex partners of patients.





(heterosexual men) 30–40 10–43
PID  8–54    36
Epididymitis
(men <35 years of age)    50 10–43†
Gonococcal infection
Men  5–30    40
Women 25–50 Unknown
*Unpublished review of literature.
†Expected to approximate or exceed prevalence for partners of men with NGU.
NOTE: Chlamydia may be a relatively uncommon cause of NGU or PID in some patient care
settings. In such settings, immediate treatment, including an antibiotic regimen for
chlamydia is warranted, but clinicians may refer sex partners contingent upon a positive test
result for C. trachomatis  or N. gonorrhoeae.
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Screening Women for Chlamydial Infection
Screening of women for chlamydial infection is a principal element of a chlamydia
prevention program (see Health-Care Provider Strategies). The decision to provide
treatment for patients whose screening results are positive and to evaluate and treat
their sex partners depends upon the patient’s risk for a sexually transmitted infection
and the potential for adverse psychosocial consequences. A positive second chlamy-
dia test strongly supports the validity of a positive screening test; a negative second
test following a positive second test does not rule out chlamydial infection.
Verification of the initial positive chlamydia test result should be obtained for per-
sons who have a positive nonculture chlamydia test and who are at low risk for
infection (e.g., involved in a monogamous relationship, have no history of sexually
transmitted infection, member of low-prevalence [<5%] patient populations) or for
whom a misdiagnosis of chlamydial infection could lead to social/psychological dis-
tress. If verification of the initial positive chlamydia test result is indicated, these
patients and their sex partners should be treated while waiting for the results of the
supplementary test. The health-care provider should postpone treatment and partner
referral only if the likelihood and adverse consequences of a false-positive test out-
weigh the risks of transmission and disease progression. Risk factors for chlamydial
infection and the probability that the patient will return for follow-up visits should also
be considered. (see Nonculture Chlamydia Tests and Clinician-Laboratory Protocols
for Verifying Positive Tests).
Screening Men for Chlamydial Infection
Screening tests for chlamydia would be more acceptable if urine rather than in-
traurethral swab specimens could be used. Chlamydia-specific nonculture tests (i.e.,
EIA, DFA, and nucleic acid probe tests) have not been adequately evaluated for use
with urine. However, the LET detects inflammatory cells in urine. Persons whose LET
test results are positive require further evaluation of the cause of inflammation, which
generally will be urethritis due to chlamydia, N. gonorrhoeae  or other sexually trans-
mitted agents, or occasionally a urinary tract infection unrelated to a sexually
transmitted agent. The utility of the LET in detecting urethritis has been evaluated
primarily among adolescent males for whom urinary tract infections other than ure-
thritis are rare. In this group, the sensitivity of the LET in detecting asymptomatic
chlamydial infection has varied from 46% to 100% (19,20,144,145 ). Compared with
the use of chlamydia-specific tests, the LET is inexpensive, easy-to-use, and provides





MPC  9–51      2–27†
Proctitis (homosexual males)  8–16 Unknown
Acute urethral syndrome 13–63 Unknown
*Unpublished review of literature.
†Lower value is the product of lowest reported prevalence among women with MPC multiplied
by lowest reported prevalence among partners of women with chlamydia; highest value is
the product of the highest reported prevalence among women with MPC and the highest
reported prevalence among partners of women with chlamydia.
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immediate results. Although the test cannot exclude infection among asymptomatic
males, continued evaluation of the LET is recommended to better define its usefulness
in detecting asymptomatic chlamydial (and gonococcal) infections.
Physical Examination of Sex Partners
Female partners of males with chlamydial infection should be referred for examina-
tion, chlamydia testing, and treatment. The examination and testing of female
partners is recommended because a) sensitive tests are available, and a positive test
result may lead to additional partners who are likely to be infected; b) women can be
asymptomatic but, when examined, have signs of PID, which requires more intensive
therapy; and c) women may be asymptomatically infected with other STDs. However,
information is needed on the rates of PID and other STDs among female partners of
infected men.
Male sex partners of females with chlamydial infections should be evaluated for
symptoms of chlamydia and other sexually transmitted infections and for allergy to
the treatment drug. A physical examination of male sex partners should be encour-
aged, but an examination is less important than treatment.
The examination and testing of asymptomatic male partners are recommended be-
cause a) a positive test result may lead to the treatment of additional partners who are
likely to be infected, b) men can be asymptomatically infected with other STDs, and
c) male partners may be allergic to the treatment drug. However, chlamydia tests for
asymptomatic males are insensitive. Further, low rates of other STDs among asymp-
tomatic male partners of women with chlamydial infection have been demonstrated
in limited studies. Also, many males do not have readily identifiable sources of medi-
cal care for STDs and so may be unlikely to be evaluated by a clinician even if asked to
do so by a sex partner. For some male partners of women with chlamydial infection,
therefore, it may be reasonable for the woman’s clinician to evaluate the male partner
even if, in the case of providers who do not offer health-care services for men, this
means evaluation without a physical examination. Although approaches to evaluating
male partners without a physical examination have not been adequately studied,
evaluation of the male partner could be performed at the clinician’s office or possibly
by telephone. Before prescribing treatment without an examination, the clinician
should determine that the male partner does not have symptoms suggestive of an-
other STD and is not allergic to the treatment drug.
Exposure Periods
For women with chlamydial infections and for asymptomatically infected men,
health-care providers should treat all sex partners with whom patients have ongoing
sexual relations and all other partners with whom patients have had sexual exposures
within 60 days before the date of the patient’s examination/test.
For males with symptomatic chlamydial infection, the 30-day period is sufficient to
detect person(s) who probably transmitted the infection to the index patient, as well
as recent sex partners who may have been exposed to the infection by the patient.
For males and females with asymptomatic infections, a longer exposure period
helps to identify additional infected partners. These extended periods, however, have
received insufficient evaluation to support specific recommendations. If no sexual ex-
posure has occurred within the specified exposure periods, the most recent sex
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partner is presumed to be at increased risk for chlamydial infection and should be
evaluated.
Responsibility for Referral of Sex Partners
Health-care providers should inform infected patients that they must have their sex
partners evaluated and treated. Health-care providers or health departments should
ensure the notification, evaluation, and treatment of the sex partners of patients with
chlamydial infection. Partner referral can be performed by patients (patient referral) or
by providers (provider referral). Patients who do comply with partner referral notify
their sex partners of their exposure and encourage them to be examined and treated.
Provider referrals require that third parties (e.g., health department personnel) as-
sume responsibility for notifying sex partners of their exposure and providing
evaluation and treatment.
Provider referral of partners—including field follow-up by health department
staff—is cost effective (155 ). However, because of the high prevalence of chlamydial
infection among some populations and the limited number of health department out-
reach workers, patient referrals remain the only method of referral available to most
clinicians.
The responsibility for evaluating the sex partners of persons with chlamydial infec-
tion is often unclear and is a major reason partners remain untreated. This is a
particular problem for male partners of females with chlamydial infection; male part-
ners (who are often asymptomatic) may be reluctant to visit an STD clinic. Health-care
providers who treat women with chlamydial infection should assist in making ar-
rangements for the evaluation and treatment of male partner(s). Health departments
can assist health-care providers in developing effective referral systems.
Clinician-Laboratory Protocols for Verifying Positive Tests
Clinician-laboratory protocols for chlamydia testing are necessary to maximize the
benefits of testing for chlamydia while minimizing adverse consequences and cost.
These protocols should address which initial and supplementary tests the laboratory
will perform, how clinicians should request these tests, and what specimens the clini-
cians should collect and submit to the laboratory during the patient’s initial and
follow-up visits. State and local health departments should facilitate the collaboration
between health-care providers and laboratories that is necessary to develop suitable
testing protocols (See Nonculture Chlamydia Tests).
When developing clinician-laboratory protocols for chlamydia testing, the preva-
lence of chlamydial infection in the patient population should be considered. In
settings with a high prevalence of infection (e.g., false-positive test results account for
a small proportion of total positive test results), initial positive test results might only
be verified if requested by the clinician on the basis of an assessment of a patient’s risk
for infection and the potential adverse effects of a false-positive result. In settings with
a low prevalence of infection (e.g., false-positive test results account for a substantial
proportion of total positive test results), an additional test for verification should be
performed on all patients whose screening test results are positive.
Three alternative testing protocols are suitable for supplementary testing. With the
first protocol, a test system is chosen that permits performing the supplementary test
on the residual material from the initial specimen. With the second protocol, a test
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system is chosen in which the supplementary test is performed on a second speci-
men. The clinician routinely obtains the second specimen at the same time as the
initial specimen and submits both specimens to the laboratory; the supplementary
test is performed on the second specimen if the initial test is positive and verification
is required. With the third protocol, the laboratory reports a positive result from the
initial test to the clinician who arranges the patient’s return visit for treatment and then
obtains a second specimen for a supplemental test. In most settings, one of the first
two protocols is preferable since they do not require a return visit to collect an addi-
tional specimen. The choice of supplementary test systems and related protocols is
difficult because insufficient information is available regarding their comparative per-
formance and cost.
ANTIMICROBIAL REGIMENS
Recommendations for the treatment of genital chlamydial infections have been
published (146,156 ). Two new antimicrobials approved by the FDA for the treatment
of chlamydia—ofloxacin and azithromycin—offer the clinician additional therapeutic
choices. A substantial advantage of azithromycin, in comparison with all other thera-
pies, is that a single dose is effective; this antimicrobial may prove most useful in
situations in which compliance with a 7-day regimen of another antimicrobial cannot
be ensured. In view of the high efficacy of tetracycline and doxycycline, cost also
should be considered when selecting a treatment regimen.
The recommended treatment regimens for uncomplicated urethral, endocervical,
or rectal chlamydial infections among adults are listed below:
• Doxycycline 100 mg orally 2 times a day for 7 days
                                  or
• Azithromycin 1 gm orally in a single dose
NOTE: Doxycycline and azithromycin are not recommended for use during pregnancy.
Alternative Treatment Regimens
Alternative treatment regimens for uncomplicated urethral, endocervical, or rectal
chlamydial infections among adults are listed below:
• Ofloxacin 300 mg orally 2 times a day for 7 days
                                  or
• Erythromycin base 500 mg orally 4 times a day for 7 days
                                  or
• Erythromycin ethylsuccinate 800 mg orally 4 times a day for 7 days
                                  or
• Sulfisoxazole 500 mg orally 4 times a day for 10 days
NOTE: Ofloxacin is not recommended for treating adolescents ≤17 years of age nor for
pregnant women. The efficacy of sulfisoxazole is inferior to other regimens. 
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The recommended treatment regimen for chlamydial infection during pregnancy is
stated below:
• Erythromycin base 500 mg orally 4 times a day for 7 days
If this regimen cannot be tolerated, the following regimens are recommended: 
• Erythromycin base 250 mg orally 4 times a day for 14 days
                                  or
• Erythromycin ethylsuccinate 800 mg orally 4 times a day for 7 days
                                  or
• Erythromycin ethylsuccinate 400 mg orally 4 times a day for 14 days
If the patient cannot tolerate erythromycin, the following regimen is recommended: 
• Amoxicillin 500 mg orally 3 times a day for 7–10 days
NOTE: Erythromycin estolate is contraindicated during pregnancy, since drug-related
hepatotoxicity can result.
For the treatment of complicated chlamydial infection, chlamydia-associated con-
ditions, and chlamydial infection among infants or children, see the 1993 Sexually
Transmitted Diseases Treatment Guidelines  (146 ) for the treatment of adults, and the
American Academy of Pediatrics Report of the Committee on Infectious Diseases
(157 ) for the treatment of infants and children.
Follow-up of Patients Treated for Chlamydial Infection
Treatment failure, indicated by positive cultures 7–14 days after therapy, is uncom-
mon after successful completion of a ≥7 day regimen of tetracycline or doxycycline;
failure rates of 0%–3% have been reported for males and 0%–8% for females
(156,158 ). However, in one study of adolescents followed up to 24 months after ther-
apy for chlamydial infection, rates of infection were 39% (118 ). Whether these
infections are reinfections or cases of latent, unsuccessfully treated chlamydial infec-
tion is unknown. Further, some studies suggest that women with chlamydial
infections are at increased risk for subsequent infection.
Although routine test-of-cure visits during the immediate post-treatment period are
not recommended, health-care providers should consider retesting females infected
with chlamydia weeks to months after initial therapy (see Nonculture Chlamydia
Tests).
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SURVEILLANCE AND PROGRAM EVALUATION
Information should be collected at the national, state, and local levels to provide
quantitative estimates of disease occurrence, monitor trends, and monitor interven-
tions and evaluate their impact. The epidemiologic analysis of surveillance and
intervention data should be the basis for decision-making in chlamydia prevention
programs, including allocation of intervention resources and evaluation of prevention
efforts. In addition, these data can be used to develop hypotheses for etiologic and
intervention research.
Surveillance of chlamydial infections is difficult for four reasons. First, the preva-
lence rate is high and the potential burden of reporting cases correspondingly large.
Second, many infected patients are asymptomatic and, therefore, are difficult to iden-
tify except through screening programs. Third, because the duration of infection
cannot be determined for many patients, prevalence and incidence are difficult to dis-
tinguish. Finally, maintaining a surveillance system requires substantial resources for
laboratory testing and information systems.
Reporting Laws
All states should have laws or regulations requiring that information on cases of
chlamydial infection be reported to the appropriate public health departments.
• Reporting laws or regulations should acknowledge chlamydia as a public health
problem and should provide the legal basis for establishing chlamydia surveil-
lance systems.
• Reporting laws or regulations should allow states to collect information regard-
ing cases of chlamydial infection from health-care providers and laboratories.
Specific categories of data should include demographics (age, race/ethnicity, sex,
geographic location, source of report), clinical characteristics (anatomic site,
symptoms/signs, treatment), and behaviors (risk factors).
NOTE: In many areas, reporting laws or regulations are also important because they
are linked to the laws and regulations that authorize health departments to initiate and
support prevention activities such as screening and partner notification.
Reportable Conditions
The recommended surveillance definition is a case of chlamydial infection diag-
nosed by a positive laboratory test result. If tests are performed to verify a positive
chlamydia test result, reporting should be contingent on verification of the initial posi-
tive test result. Reports of chlamydial complications or of conditions serving as
surrogates for chlamydial infection—when chlamydia tests are not available—should
be analyzed separately.
NGU, PID, ophthalmia neonatorum, and epididymitis are the principal conditions
that might be reported as complications of, or surrogates for, chlamydial infection.
The performance of chlamydia tests and their results should be included with reports
of these conditions.
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Establishing a Surveillance System
To measure chlamydia trends accurately, identify populations with an increased
frequency of chlamydial infection and to estimate the burden of chlamydia disease,
health departments should develop active chlamydia surveillance systems. These sys-
tems should incorporate the following recommendations:
• Encourage participation by private and public health-care providers and labora-
tories to ensure that results are representative of the whole population.
• Include measures of incidence as well as prevalence of chlamydial infections.
• Use screening results as an index of the prevalence of asymptomatic chlamydial
infection.
Monitoring Incidence
Health departments should monitor chlamydia incidence by collecting information
regarding men who seek care because of symptoms of urethritis. If tests are per-
formed, the results of chlamydia and gonorrhea laboratory tests should be included
with reported cases of urethritis. If chlamydia testing is not performed, the reported
incidence of NGU should be used as an index of chlamydia incidence.
Monitoring Prevalence (Screening)
The number of chlamydia cases identified by community screening programs
should be monitored as an index of chlamydia prevalence. Information on the follow-
ing factors that affect the number of chlamydia cases detected should also be
collected:
• Number of chlamydia tests being performed
• Reason for chlamydia testing (e.g., asymptomatic screening or diagnostic testing
performed because of symptoms)
• Characteristics of the population undergoing chlamydia testing
In some states, the volume of chlamydia cases precludes collecting sufficient infor-
mation on each case of chlamydia. These states should develop community-based
sentinel surveillance to monitor trends in the distribution of chlamydial infections and
disease burden by demographic, behavioral, and clinical factors.
With a sentinel system, a group of health-care providers serving patients who are
representative of select populations in the community are recruited to monitor
chlamydial infection rates. Examples of potential sentinel sites include STD clinics,
family planning clinics, prenatal-care providers, community health centers, school
health providers, jails and detention centers, and group practices or health mainte-
nance organizations.
A sentinel site monitoring the prevalence of chlamydia should test all patients (or a
given number of consecutive patients or a random or systematic sample of patients)
for chlamydial infection regardless of the patient’s chief complaint or symptom status.
Demographic, behavioral, and clinical information should be recorded for all patients
tested. A sentinel site that monitors the incidence of NGU should collect information
30 MMWR August 6, 1993
on all male patients with symptoms of urethritis and negative test results for gonor-
rhea. When possible, sentinel sites should monitor the prevalence of gonococcal
infections and the incidence of gonococcal urethritis for all patients and the key se-
quelae of chlamydial and gonococcal infections (e.g., PID, infertility, ectopic
pregnancy).
Laboratory Surveillance
Because the surveillance definition of chlamydial infection requires laboratory test-
ing, local laboratories are an important component of a chlamydia surveillance
system. Health departments should establish an inventory of laboratories conducting
chlamydia testing and poll them regularly for the number of chlamydia tests per-
formed and the number of positive test results.
Monitoring Interventions
Chlamydia prevention programs should monitor intervention activities. Health de-
partments should monitor the extent and quality of the interventions (process
evaluation). Data should be analyzed to determine whether chlamydia trends (meas-
ured by surveillance systems) can be linked to interventions (outcome evaluation).
Screening and partner notification are interventions of particular interest. The follow-
ing guidelines are recommended:
• To permit health departments to monitor screening programs, participating
health-care providers should provide screening test results (see Monitoring
Prevalence).
• Where substantial resources are allocated to partner notification or other inter-
ventions, health departments should monitor these activities to ensure optimal
distribution of those resources.
ORGANIZING STRATEGIC PARTNERSHIPS
The primary goal of a chlamydia prevention strategy should be to secure the re-
sources to provide adolescents and young adults with access to information
regarding chlamydial infection, screening and treatment services, and partner notifi-
cation. Meeting this goal will require the cooperation of all agencies and programs
that serve the health-care needs of adolescents and young adults. Every community
has an opportunity to provide appropriate educational material regarding STDs and
sexual behaviors, and to make screening and treatment for STDs more readily avail-
able to those at high risk for chlamydial infection. For example, some family planning
programs provide chlamydia testing and treatment for their clients and their male sex
partners, and a similar service is provided in some STD clinics. However, these efforts
reach only a portion of the population that is infected with chlamydia. Such programs
should be expanded to include other primary care providers who deliver medical serv-
ices to sexually active adolescents and young adults—community health centers,
migrant health centers, Native-American health centers, school-based clinics, Job
Corps, detention centers, active-duty military facilities, hospital emergency rooms,
and providers in the private sector. Schools, community-based recreational and after-
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school programs such as YMCAs, and other agencies can offer information about
STDs (including HIV infection).
A successful chlamydia prevention program should effectively coordinate all re-
sources in a community. State STD/HIV prevention programs can provide solutions
since their staff have experience in organizing clinical, educational, and laboratory re-
sources within states, and they have developed partnerships with providers
(e.g., family planning, prenatal, and migrant health clinics) who are part of any pre-
vention program. The challenge is to focus on the common problem—high rates of
chlamydial infection throughout the country—and to develop the interagency relation-
ships and coalitions that are needed to deliver appropriate chlamydia services in both
public and private settings.
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